Skip to main content
Top
Published in: Cardiology and Therapy 4/2023

Open Access 20-10-2023 | Atrial Flutter | Original Research

Comparative Effectiveness of Various Radiofrequency Ablation Catheters in the Ablation of Typical Atrial Flutter

Authors: Asher Gorantla, Mahmoud Alsaiqali, Jonathan Francois, Shruthi Sivakumar, Leonell Freytes-Santiago, Ahmad Jallad, Adam S. Budzikowski

Published in: Cardiology and Therapy | Issue 4/2023

Login to get access

Abstract

Introduction

Although ablation of typical atrial flutter (AFL) can be easily achieved with radiofrequency energy (RF), no studies compare the effectiveness of different ablation catheters. Our study aimed to compare the efficacy of various types of ablation catheters in treating typical AFL.

Methods

We analyzed patients with AFL who underwent RF ablation by a single operator at our institution. Successful ablation was evidenced by a bidirectional conduction block (trans-isthmus conduction time ≥ 130 ms or double potentials ≥ 90 ms). Logistic regression was used to compare success rate and linear regression to compare lesion time.

Results

Out of 222 patients, only six did not meet the success criteria (2.7%). The catheters used were non-irrigated, large-tip, internally irrigated (Chili II Boston Scientific), and externally irrigated (non-force-sensing) catheters (Cool Path, Abbott). An externally irrigated force-sensing catheter (TactiCath, Abbott) was used with > 10 gm of force and (LPLD) setting (30 W− 45 °C− 60 s), and high-power short-duration (HPSD) setting (50 W− 43 °C − 12 s). No complications were encountered. The catheter type had no statistically significant association with ablation success. With the use of externally irrigated catheter with contract force-sensing and HPSD settings, statistically significantly shortening of lesion time was achieved 758.3 s, [CI − 1128.29, − 388.35 s] followed by LPLD by 419.0 s [CI − 808.49, − 29.47 s].

Conclusions

The typical atrial flutter radiofrequency ablation procedure had a high success rate, which was not influenced by the type of ablation catheter. Contact force ablation catheter and HPSD are associated with shorter total lesion time.
Literature
1.
go back to reference Sok-Sithikun B, Decebal GL, Francis M, Nadir S. Atrial flutter: more than just one of a kind. Eur Heart J. 2015;36(35):2356–63.CrossRef Sok-Sithikun B, Decebal GL, Francis M, Nadir S. Atrial flutter: more than just one of a kind. Eur Heart J. 2015;36(35):2356–63.CrossRef
2.
go back to reference Kacprzyk M, Kuniewicz M, Lelakowski J. Trzepotanie przedsionków w praktyce kardiologa [Atrial flutter in cardiology practice]. Pol Merkur Lekarski. 2020;48(285):204–8.PubMed Kacprzyk M, Kuniewicz M, Lelakowski J. Trzepotanie przedsionków w praktyce kardiologa [Atrial flutter in cardiology practice]. Pol Merkur Lekarski. 2020;48(285):204–8.PubMed
3.
go back to reference Daubert JP, Budzikowski AS, Feld G. Cryoablation of cavotricuspid valve isthmus-dependent atrial flutter. In: Khairy P, Dubuc M, editors. Cryoablation for cardiac arrhythmias. Vision Communications; 2008. p. 61–81. Daubert JP, Budzikowski AS, Feld G. Cryoablation of cavotricuspid valve isthmus-dependent atrial flutter. In: Khairy P, Dubuc M, editors. Cryoablation for cardiac arrhythmias. Vision Communications; 2008. p. 61–81.
7.
go back to reference Sacher F, O’Neill MD, Jais P, Huffer LL, Laborderie J, Derval N, Deplagne A, Takahashi Y, Jonnson A, Hocini M, Clementy J, Haissaguerre M. Prospective randomized comparison of 8-mm gold-tip, externally irrigated-tip and 8-mm platinum-iridium tip catheters for cavotricuspid isthmus ablation. J Cardiovasc Electrophysiol. 2007;18(7):709–13. https://doi.org/10.1111/j.1540-8167.2007.00861.x.CrossRefPubMed Sacher F, O’Neill MD, Jais P, Huffer LL, Laborderie J, Derval N, Deplagne A, Takahashi Y, Jonnson A, Hocini M, Clementy J, Haissaguerre M. Prospective randomized comparison of 8-mm gold-tip, externally irrigated-tip and 8-mm platinum-iridium tip catheters for cavotricuspid isthmus ablation. J Cardiovasc Electrophysiol. 2007;18(7):709–13. https://​doi.​org/​10.​1111/​j.​1540-8167.​2007.​00861.​x.CrossRefPubMed
13.
go back to reference Winkle RA, Mohanty S, Patrawala RA, et al. Low complication rates using high power (45–50 W) for short duration for atrial fibrillation ablations. Heart Rhythm. 2019;16:165–9.CrossRefPubMed Winkle RA, Mohanty S, Patrawala RA, et al. Low complication rates using high power (45–50 W) for short duration for atrial fibrillation ablations. Heart Rhythm. 2019;16:165–9.CrossRefPubMed
14.
go back to reference Bourier F, Duchateau J, Vlachos K, et al. High-power short-duration versus standard radiofrequency ablation: Insights on lesion metrics. J Cardiovasc Electrophysiol. 2018;29:1570–5.CrossRefPubMed Bourier F, Duchateau J, Vlachos K, et al. High-power short-duration versus standard radiofrequency ablation: Insights on lesion metrics. J Cardiovasc Electrophysiol. 2018;29:1570–5.CrossRefPubMed
15.
go back to reference Bhaskaran A, Chik W, Pouliopoulos J, et al. Five seconds of 50–60 W radio frequency atrial ablations were transmural and safe: an in vitro mechanistic assessment and force-controlled in vivo validation. Europace. 2017;19:874–80.PubMed Bhaskaran A, Chik W, Pouliopoulos J, et al. Five seconds of 50–60 W radio frequency atrial ablations were transmural and safe: an in vitro mechanistic assessment and force-controlled in vivo validation. Europace. 2017;19:874–80.PubMed
16.
go back to reference Leshem E, Zilberman I, Tschabrunn CM, et al. High-power and short-duration ablation for pulmonary vein isolation: biophysical characterization. JACC Clin Electrophysiol. 2018;4:467–547.CrossRefPubMed Leshem E, Zilberman I, Tschabrunn CM, et al. High-power and short-duration ablation for pulmonary vein isolation: biophysical characterization. JACC Clin Electrophysiol. 2018;4:467–547.CrossRefPubMed
17.
go back to reference Heart Rhythm O2 Volume 1, Issue 5, December 2020, Pages 317–323 Heart Rhythm O2 Volume 1, Issue 5, December 2020, Pages 317–323
Metadata
Title
Comparative Effectiveness of Various Radiofrequency Ablation Catheters in the Ablation of Typical Atrial Flutter
Authors
Asher Gorantla
Mahmoud Alsaiqali
Jonathan Francois
Shruthi Sivakumar
Leonell Freytes-Santiago
Ahmad Jallad
Adam S. Budzikowski
Publication date
20-10-2023
Publisher
Springer Healthcare
Keyword
Atrial Flutter
Published in
Cardiology and Therapy / Issue 4/2023
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-023-00336-3

Other articles of this Issue 4/2023

Cardiology and Therapy 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.